Skip to content

Investors / Press Releases


The press releases contained in this section of the website are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. Amarin disavows any obligation to update the information contained in such press releases after the date of their issuance.


Filter Releases
 
Press Releases
Date Title and Summary View
Oct 27, 2016
BEDMINSTER, N.J. and DUBLIN, Ireland, Oct. 27, 2016 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, today announced that it will host a conference call with members of Amarin senior management to discuss the com...
Oct 25, 2016
BEDMINSTER, N.J. and DUBLIN, Ireland, Oct. 25, 2016 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) announced today the introduction of a smaller 0.5-gram capsule size for Vascepa® (icosapent ethyl) available now in retail pharmacies nationwide. The smaller capsule is in addition to the original and currently available 1-gram size V...
Sep 12, 2016
BEDMINSTER, N.J. and DUBLIN, Ireland, Sept. 12, 2016 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) announced that, as expected, the independent data monitoring committee (DMC) has completed its review of the first pre-specified interim efficacy analysis for the REDUCE-IT cardiovascular outcomes study and has recommended that the trial ...
Sep 7, 2016
BEDMINSTER, N.J., and DUBLIN, Ireland, Sept. 07, 2016 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced that John F. Thero, Amarin's president and chief executive officer, is scheduled to present a gener...
Aug 31, 2016
BEDMINSTER, N.J. and DUBLIN, Ireland, Aug. 31, 2016 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) announced that randomization of patients into the REDUCE-IT cardiovascular outcomes study has been completed with 8,175 individual patients randomized, in accordance with the study protocol, on a 1:1 basis between Vascepa® (icosapent ...
Aug 26, 2016
BEDMINSTER, N.J. and DUBLIN, Ireland, Aug. 26, 2016 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) ("Amarin"), announced today that its wholly owned subsidiary, Corsicanto Limited, a private limited company incorporated under the laws of Ireland (the "Issuer"), provided notice that the Issuer has exercised its option to mandatorily exch...
Aug 15, 2016
BEDMINSTER, N.J. and DUBLIN, Ireland, Aug. 15, 2016 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that, in connection with its previously announced underwritten public offering of American Depositary Shares ("ADSs"), the underwriters of the offering have exercised in full their option to purchase up to an aggregate of 3...
Aug 11, 2016
BEDMINSTER, N.J., and DUBLIN, Ireland, Aug. 11, 2016 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced the pricing of an underwritten public offering of 21,100,000 American Depositary Shares ("ADSs") at a price to the public of $2.85 per ADS. The net proceeds to the company from this offering are expected to be approximatel...
Aug 10, 2016
BEDMINSTER, N.J., and DUBLIN, Ireland, Aug. 10, 2016 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it has commenced an underwritten public offering of its American Depositary pursuant to a shelf registration.  All of the shares in the proposed offering are to be sold by Amarin.  The offering is subject to market co...
Aug 4, 2016
BEDMINSTER, NJ and DUBLIN, IRELAND -- (Marketwired) -- 08/04/16 -- Amarin Corporation plc (NASDAQ: AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, today announced financial results for the three and six months ended June 30, 2016, and provided an update on compan...
Aug 4, 2016
BEDMINSTER, NJ and DUBLIN, IRELAND -- (Marketwired) -- 08/04/16 -- Amarin Corporation plc (NASDAQ: AMRN) today announced that the U.S. Food and Drug Administration (FDA) agreed to an amendment of the company's special protocol assessment (SPA) agreement for the REDUCE-IT cardiovascular outcomes study reaffirming concurrence on critical components...
Jul 28, 2016
BEDMINSTER, NJ and DUBLIN, IRELAND -- (Marketwired) -- 07/28/16 -- Amarin Corporation plc (NASDAQ: AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, today announced that it will host a conference call with members of Amarin senior management to discuss the company'...
Jul 6, 2016
BEDMINSTER, NJ and DUBLIN, IRELAND -- (Marketwired) -- 07/06/16 -- Amarin Corporation plc (NASDAQ: AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that John F. Thero, Amarin's president and chief executive officer, is scheduled to present a gen...
Jun 30, 2016
BEDMINSTER, NJ and DUBLIN, IRELAND -- (Marketwired) -- 06/30/16 -- Amarin Corporation plc (NASDAQ: AMRN) announced that starting today Michael W. Kalb has joined its senior management team as senior vice president and chief financial officer. A seasoned financial executive, Mr. Kalb brings over 20 years of international financial operations and acc...
Jun 11, 2016
BEDMINSTER, NJ and DUBLIN, IRELAND -- (Marketwired) -- 06/11/16 -- Amarin Corporation plc (NASDAQ: AMRN) today announced additional data on Vascepa (icosapent ethyl) presented at the annual meeting of the American Diabetes Association (ADA) supporting its efficacy in reducing concentrations of potentially atherogenic lipoproteins (lipoproteins th...
= add release to Briefcase